Article summary
The National Institute for Health and Care Excellence (NICE) has published a statement on its work to prepare for the end of the transition period. NICE has stated that it is working with the Medicines and Healthcare products Regulatory Agency (MHRA) to develop processes for licensing and evaluating new medicines for use in the NHS after IP completion day and to improve access to medical devices in the UK that are registered with the MHRA.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial